MicroRNA-155 attenuates activation of hepatic stellate cell by simultaneously preventing EMT process and ERK1 signalling pathway

Liver International

Volumn 35, Issue 4, 2015, Pages 1234-1243

  Dai, Weiping ^a   Zhao, Juan ^a   Tang, Nan ^a   Zeng, Xin ^a   Wu, Kaiming ^a   Ye, Changhong ^a   Shi, Jian ^a   Lu, Cuihua ^b   Ning, Beifang ^a   Zhang, Junping ^c   Lin, Yong ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition (EMT); Extracellular signal regulated kinase 1 (ERK1) signalling pathway; Hepatic stellate cell (HSC); MicroRNA 155; Regulation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; MESSENGER RNA; MICRORNA 155; MITOGEN ACTIVATED PROTEIN KINASE 3; RAS PROTEIN; T CELL FACTOR 4; T CELL FACTOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; 3' UNTRANSLATED REGION; DNA BINDING PROTEIN; MICRORNA; MIRN155 MICRORNA, HUMAN; MIRN155 MICRORNA, RAT; TCF4 PROTEIN, RAT; TRANSCRIPTION FACTOR;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; LUCIFERASE ASSAY; MALE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; RNA TRANSLATION; SIGNAL TRANSDUCTION; STELLATE CELL; UPREGULATION; ANIMAL; BINDING SITE; CASE CONTROL STUDY; ENZYMOLOGY; EXPERIMENTAL LIVER CIRRHOSIS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; LIVER; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BINDING SITES; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HEK293 CELLS; HEPATIC STELLATE CELLS; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER CIRRHOSIS, EXPERIMENTAL; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 3; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84924577483     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12660     Document Type: Article

References (40)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
3. Qiang H, Lin Y, Zhang X, et al. Differential expression genes analyzed by cDNA array in the regulation of rat hepatic fibrogenesis. Liver Int 2006; 26: 1126-37.
4. Wang Y, Gao J, Zhang D, et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132-44.
5. Bataller R, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal 2005; 7: 1346-55.
6. Moreno M, Gonzalo T, Kok RJ, et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010; 51: 942-52.
7. Kisseleva T, Cong M, Paik Y, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 2012; 109: 9448-53.
8. Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut 2002; 50: 891-6.
9. Zhong W, Shen WF, Ning BF, et al. Inhibition of extracellular signal-regulated kinase 1 by adenovirus mediated small interfering RNA attenuates hepatic fibrosis in rats. Hepatology 2009; 50: 1524-36.
10. Ikegami T, Zhang Y, Matsuzaki Y. Liver fibrosis: possible involvement of EMT. Cells Tissues Organs 2007; 185: 213-21.
11. Kaimori A, Potter JJ, Choti M, et al. Histonedeacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology 2010; 52: 1033-45.
12. Pinzani M. Epithelial-mesenchymal transition in chronic liver disease: fibrogenesis or escape from death? J Hepatol 2011; 55: 459-65.
13. Yue HY, Yin C, Hou JL, et al. Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut 2010; 59: 236-46.
14. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-5.
15. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011; 157: 191-9.
16. Vettori S, Gay S, Distler O. Role of MicroRNAs in Fibrosis. Open Rheumatol J 2012; 6: 130-9.
17. Noetel A, Kwiecinski M, Elfimova N, Huang J, Odenthal M. microRNA are central players in anti- and profibrotic gene regulation during liver fibrosis. Front Physiol 2012; 3: 49. Epub 2012 Mar 19.
18. Murakami Y, Tanahashi T. Analysis of circulating microRNA by microarray in liver disease. Methods Mol Biol 2013; 1024: 173-82.
19. Chen YP, Jin X, Xiang Z, Chen SH, Li YM. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int 2013; 33: 1257-65.
20. Miller AM, Gilchrist DS, Nijjar J, et al. miR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS ONE 2013; 21: e72324.
21. Xiang X, Zhuang X, Ju S, et al. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene 2011; 30: 3440-53.
22. Boj SF, van Es JH, Huch M, et al. Diabetes risk gene and Wnt effector Tcf7 l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 2012; 151: 1595-607.
23. Yoneda M, Hotta K, Nozaki Y, et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 2009; 29: 1078-85.
24. Aplin M, Christensen GL, Schneider M, et al. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin Pharmacol Toxicol 2007; 100: 289-95.
25. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-4.
26. Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011; 91: 579-87.
27. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008; 111: 1217-26.
28. Venugopal SK, Jiang J, Kim TH, et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol 2010; 298: G101-6.
29. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206.
30. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009; 25: 223-9.
31. Lakner AM, Steuerwald NM, Walling TL, et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology 2012; 56: 300-10.
32. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
33. Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53: 209-18.
34. Ogawa T, Enomoto M, Fujii H, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012; 61: 1600-9.
35. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008; 48: 1810-20.
36. Morita K, Taketomi A, Shirabe K, et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 2011; 31: 474-84.
37. Sánchez-Tilló E, de Barrios O, Siles L, et al. β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A 2011; 108: 19204-9.
38. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006; 281: 18277-84.
39. Novo E, Marra F, Zamara E, et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006; 55:1174-82.
40. Liu Y, Lui EL, Friedman SL, et al. PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. Lab Invest 2009; 89: 209-21.